OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY.

Trial Profile

OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Imatinib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top